$PFE News You'd have to be a dope to buy marijuana stocks

New Post Public Reply Private Reply Replies (0) Message Board

Feb 20, 2014 at 11:43 AM

$PFE News

You'd have to be a dope to buy marijuana stocks 1:36 p.m. Feb. 13, 2014 - blogs.marketwatch.com
Australia regulator takes action against Pfizer 11:03 p.m. Feb. 12, 2014 - MarketWatch.com
Pfizer, GE, Boeing lead early Dow advancers 9:34 a.m. Feb. 11, 2014 - William L. Watts
Judge likely to throw the book at Martoma, experts say 4:00 p.m. Feb. 6, 2014 - blogs.marketwatch.com
Feds, pharma rivals team up on Alzheimer's 2:32 p.m. Feb. 6, 2014 - blogs.marketwatch.com
The big Merck news centers on cancer-drug collaborations with other giants 11:02 a.m. Feb. 5, 2014 - blogs.marketwatch.com
Merck 4Q profit falls on weaker sales 8:21 a.m. Feb. 5, 2014 - MarketWatch.com
Stock market live blog: Indexes break 2-day losing streak; Kors, Yum climb 3:43 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow after an upgrade on promising cancer-drug tests 11:07 a.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow with 3% gain following upgrade 10:11 a.m. Feb. 4, 2014 - Russ Britt
Pfizer leads Dow with 3.3% gain following upgrade 10:03 a.m. Feb. 4, 2014 - Russ Britt
Pfizer advances 4.2% at the open, leads Dow 9:33 a.m. Feb. 4, 2014 - Victor Reklaitis
U.S. stocks see worst selloff in several months 4:41 p.m. Feb. 3, 2014 - Anora Mahmudova
Biggest drops since June for Dow industrials, S&P 500: stock market live blog recap 4:26 p.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer, Randgold gain in slumping stock market 3:52 p.m. Feb. 3, 2014 - Saumya Vaishampayan
Pfizer shares get a boost on positive results for breast-cancer treatment 10:37 a.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer breast-cancer study meets endpoint 8:37 a.m. Feb. 3, 2014 - MarketWatch.com
The inscrutable gold timers 10:26 a.m. Jan. 30, 2014 - Mark Hulbert
Updates, advisories and surprises 5:31 p.m. Jan. 28, 2014 - MarketWatch
U.S. stocks rise; Dow breaks 5-day skid 5:02 p.m. Jan. 28, 2014 - Anora Mahmudova

Pfizer Inc (PFE): Today's Featured Drugs Laggard 5:01 p.m. Feb. 19, 2014 - TheStreet.com
Wall Street Winners: Were Analyst 2014 Picks Worth Their Salt? 8:53 a.m. Feb. 18, 2014 - Seeking Alpha
If Adam Smith Were Alive, He'd Be A Dividend Investor 6:51 a.m. Feb. 15, 2014 - Seeking Alpha
If Adam Smith Were Alive, He Would Be A Dividend Investor 6:51 a.m. Feb. 15, 2014 - Seeking Alpha
Dow Today: Pfizer (PFE) Leads The Day Higher, AT&T (T) Lags 10:00 a.m. Feb. 14, 2014 - TheStreet.com
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer Needs a Healthy Dose of Investor Love 6:00 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer's Finally a Buy 1:13 p.m. Feb. 13, 2014 - Barrons.com
10 Reasons To Buy Durect Right Now 10:45 a.m. Feb. 13, 2014 - Seeking Alpha
Australian regulator sues Pfizer over Lipitor sales tactics 9:58 a.m. Feb. 13, 2014 - Seeking Alpha
Pfizer Australia Faces Antitrust Probe 12:05 a.m. Feb. 13, 2014 - WSJ.com
Update on Bayer's Aleve - Analyst Blog 4:45 p.m. Feb. 12, 2014 - Zacks.com
Stock Market News for February 12, 2014 - Market News 10:06 a.m. Feb. 12, 2014 - Zacks.com
FDA News: Aleve Is Not Safer Than Advil, Ibuprofen & Celebrex 5:50 a.m. Feb. 12, 2014 - InvestorPlace.com
FDA Panel Rejects Changing Painkiller Labels 5:32 p.m. Feb. 11, 2014 - WSJ.com
Marginal Earnings Beat at Zoetis in Q4, Guidance Weak - Analyst Blog 10:57 a.m. Feb. 11, 2014 - Zacks.com
Zoetis Q4 Beats Estimates, But Guidance Hammers Stock 10:32 a.m. Feb. 11, 2014 - Investors Business Daily
Stock Market News for February 11, 2014 - Market News 10:06 a.m. Feb. 11, 2014 - Zacks.com
Pfizer Inc Stock Buy Recommendation Reiterated (PFE) 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Zoetis Swings to Fourth-Quarter Profit 7:58 a.m. Feb. 11, 2014 - WSJ.com

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference 10:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership 11:02 a.m. Feb. 13, 2014 - ACCESSWIRE
Northeast Shows Nearly $7 Billion in Reasons to Love the Life Science Industry's Capital Investments, an Industrial Info News Alert 6:15 a.m. Feb. 13, 2014 - Marketwire
Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees 2:03 p.m. Feb. 11, 2014 - BusinessWire - BZX
Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014 10:48 p.m. Feb. 4, 2014 - GlobeNewswire
LiveWorld and Pfizer to Present a Series of Panels on Social Media Within Regulated Industries at Social Media Week 10:00 a.m. Feb. 4, 2014 - BusinessWire - BZX
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market 9:05 a.m. Feb. 4, 2014 - PR Newswire - PRF
TrendingWallStreet.com Initiates Trend Analysis on GFOX, CMCSA, SKTO, and PFE 12:22 a.m. Feb. 4, 2014 - ACCESSWIRE
Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer 7:00 a.m. Feb. 3, 2014 - BusinessWire - BZX
Critical Alerts For Twitter, Alexion Pharmaceuticals, Pfizer, Ctrip, and AngloGold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 31, 2014 - PR Newswire - PRF
Pfizer Reports Fourth-Quarter and Full-Year 2013 Results;Provides 2014 Financial Guidance 7:01 a.m. Jan. 28, 2014 - BusinessWire - BZX
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 7:00 a.m. Jan. 27, 2014 - BusinessWire - BZX
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 8:00 a.m. Jan. 23, 2014 - BusinessWire - BZX
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating 10:00 a.m. Jan. 22, 2014 - BusinessWire - BZX
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP 7:30 a.m. Jan. 22, 2014 - PR Newswire - PRF
CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly 8:00 a.m. Jan. 21, 2014 - BusinessWire - BZX
ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe 6:52 a.m. Jan. 21, 2014 - PR Newswire - PRF
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health 10:15 a.m. Jan. 17, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

USD 6.8 Million for Disease R&D: GHIT's Bold Bet

GHIT Fund Pumps Millions Into Health R&D In a world plagued by infectious disease outbreaks and continual health challenges, the Global Health Innovative Technology (GHIT) Fund isn't just twiddling its thumbs—they're throwing down around $6.8 million to wrestle some of the nastiest bugs out there, like malaria and Ebola. This cash doubles down on nine risky gambles,...

Oracle's Bold Vision: Targeting $225B Revenue by 2030

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Coffee Bean Brews Up Nostalgia with Tiramisu Treats

Pouring Old Favorites: The Tiramisu Return When the aromas of coffee and nostalgia waft through the air, it's often a sign that The Coffee Bean & Tea Leaf® is brewing something special. This year, they've decided to double down on the holiday cheer by reintroducing their wildly popular Tiramisu beverage. This ain't just your run-of-the-mill coffee drink—it's a full-on...

EQS Group Unveils 'Q': AI-Driven Compliance Revolution

Compliance in the Fast Lane The compliance world just got a hefty upgrade with EQS Group's latest rollout: 'Q by EQS,' an AI-powered intelligence layer that's here to shake up the way compliance tasks are handled. It's integrated right into the heart of the EQS Compliance Cockpit, giving teams an edge by automating those pesky, time-sucking routines and guiding them...

Liberty Systems Expands Operations with Major HQ Move

Hardly a yawn-worthy move, folks. Liberty Systems up and switched from Waukesha to Oconomowoc, boosting its digs to a sprawling 100,000-square-foot headquarters. It's a classic tale of growth for the Wisconsin-based company known for its on-site nitrogen generators and compressed air systems. Now, I'm telling you, they've more than doubled production capacity—that's a...

Bank Leumi Q3 Earnings Preview: Key Dates & Insights

A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...

Doximity Faces Legal Heat: 23% Stock Plunge Analyzed

Doximity's Rollercoaster: Steep Drop Amid Lawsuits Imagine watching your portfolio take a gut-wrenching plunge—and that's the rollercoaster ride Doximity investors experienced. On May 14, 2026, Doximity's stock nosedived by 23%, closing at $18.01 per share. This tumble, which marked a painful conclusion to a series of financial disappointments, has thrown the company...

Data Breach at Lumara Bio: Privacy Lawsuits Loom

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Wendy's Faces Takeover Bid Amid Strategic Focus Shift

Behind the Unsolicited Offer Folks, it looks like Wendy's (NASDAQ:WEN) got itself mixed up in some high-stakes shenanigans. An unsolicited, non-binding proposal slammed into them, courtesy of the Investor Group led by Trian Partners, Flynn Group LP, BlueFive Capital, and Sixth Street Partners, itching to scoop up every last piece of Wendy’s stock they ain't already...

Custom Homes Shine: Florida’s Lucrative Property Move

Why Custom Homes Are Worth the Investment in Florida Ever thought about sinking some cash into Florida's real estate game? Well, building a custom home might just be your golden ticket, according to Paul H Schaefer II from Sage Homes LLC. I mean, everyone knows Florida's housing market is as spicy as a chili pepper, but custom homes seem to be the secret sauce here....